You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Orelabrutinib

Showing 1 - 25 of 48
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Healthy Subject Trial in Beijing (Orelabrutinib and (orelabrutinib tablet simulator), Orelabrutinib, Placebo (orelabrutinib

Active, not recruiting
  • Healthy Subject
  • Orelabrutinib and placebo (orelabrutinib tablet simulator)
  • +3 more
  • Beijing, China
    Beijing GoBroad Boren Hospital
Dec 19, 2022

Orelabrutinib in Treatment of Chronic Lymphocytic Leukemia/Small

Recruiting
  • CLL/SLL
  • Orelabrutinib
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital Affiliate
Jun 16, 2023

Orelabrutinib in Combination With Standard Treatment Regimen for

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
  • Orelabrutinib
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Aug 23, 2023

Orelabrutinib in the Treatment of CLL/SLL

Not yet recruiting
  • CLL/SLL
    • (no location specified)
    Jul 26, 2023

    CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)

    Not yet recruiting
    • CNS Lymphoma
    • Orelabrutinib
    • +2 more
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Jun 22, 2023

    CLL/SLL Trial in Wuhan, Changsha (Orelabrutinib and BG)

    Not yet recruiting
    • CLL/SLL
    • Orelabrutinib and BG
    • Wuhan, Hubei, China
    • +1 more
    Jun 15, 2023

    The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

    Recruiting
    • The First Affiliated Hospital of Nanchang University
    • Nanchang, Jiangxi, China
    • +1 more
    Jul 3, 2023

    Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Marginal Zone Lymphoma
    • Orelabrutinib
    • +3 more
    • Guangzhou, Guangdong, China
    • +10 more
    Oct 8, 2023

    Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib
    • +2 more
    • Hanzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Nov 3, 2022

    Healthy Person Trial in Suzhou (Orelabrutinib + Rifampin, Orelabrutinib + Itraconazole)

    Completed
    • Healthy Person
    • Orelabrutinib + Rifampin
    • Orelabrutinib + Itraconazole
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 5, 2022

    CLL/SLL Trial in Beijing (orelabrutinib)

    Recruiting
    • CLL/SLL
    • orelabrutinib
    • Beijing, Beijing, China
    • +1 more
    Aug 5, 2022

    Hepatic Impairment Trial in China (Orelabrutinib Tablets)

    Not yet recruiting
    • Hepatic Impairment
    • Orelabrutinib Tablets
    • Bengbu, Anhui, China
    • +4 more
    Jan 12, 2023

    Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib,Rituximab and Methotrexate
    • Beijing, Beijing, China
      Hospital 307
    Sep 19, 2022

    DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Orelabrutinib
    • +2 more
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Aug 10, 2022

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Orelabrutinib + R-CHOP
    • Placebo + R-CHOP
    • Shanghai, Shanghai, China
      Shanghai Ruijing Hospital
    Nov 28, 2022

    Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib
    • +3 more
    • Shanghai, Shanghai, China
      Department of Hematology, Huashan Hospital, Fudan University
    Jul 26, 2022

    r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

    Not yet recruiting
    • B-cell Lymphoma
    • Orelabrutinib
    • Beijing, Beijing, China
      Deparment of Hematology, Peking University People's Hospital
    Aug 9, 2022

    Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

    Recruiting
    • Follicular Lymphoma
    • Relapsed and Refractory Follicular Lymphoma
    • Orelabrutinib and Rituximab
    • Orelabrutinib
    • Guangzhou, Guangdong, China
    • +2 more
    Mar 23, 2022

    Primary Immune Thrombocytopenia Trial in China (Orelabrutinib( lower dose), Orelabrutinib( higher dose))

    Recruiting
    • Primary Immune Thrombocytopenia
    • Orelabrutinib( lower dose)
    • Orelabrutinib( higher dose)
    • HaiKou, Hainan, China
    • +8 more
    Jan 10, 2023

    Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Apr 18, 2022

    Diffuse Large B Cell Lymphoma Trial in Suzhou (Rituximab, Orelabrutinib, Pomalidomide)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib
    • +3 more
    • Beijing, Beijing, China
    • +2 more
    May 19, 2022

    B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

    Active, not recruiting
    • B-cell Lymphoma Recurrent
    • B-cell Lymphoma Refractory
    • Orelabrutinib
    • Recombinant humanized monoclonal antibody MIL62 injection
    • Bengbu, Anhui, China
    • +9 more
    Nov 11, 2022

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)

    Recruiting
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Orelabrutinib
    • +3 more
    • Nanjin, Jiangsu, China
      Department of Haematology, the First Affiliated Hospital of Nanj
    Apr 12, 2022